ORDER DENYING ABBOTT’S MOTION TO DISMISS

(DOCKET NOS. 19, 23, 38, 24, 29, 44, 46, AND 18)

AND DENYING ABBOTT’S MOTION TO TRANSFER

(DOCKET NO. 19)

Defendant Abbott Labs moves to dismiss the complaint in each of these related actions, arguing that Plaintiffs’ claims for monopolization and attempted monopolization of the market for boosted protease inhibitors are foreclosed by the recent Ninth Circuit case, Cascade Health Solutions v. PeaceHealth, 515 F.3d 883 (9th Cir.2008). Abbott moves separately to dismiss GlaxoSmithKline’s (GSK) claims in the SmithKline Beecham case for breach of the implied covenant of good faith and fair dealing, violation of the North Carolina Unfair Trade Practices Act and violation of the North Carolina Prohibition Against Monopolization. Finally, Abbott moves to transfer the SmithKline Beec-ham case to Illinois. Plaintiffs oppose each of these motions. The matters were heard on March 6, 2008. Having considered oral argument and all of the papers submitted by the parties, the Court denies Abbott’s motions.

BACKGROUND

Protease inhibitors (Pis) are considered the most potent class of drugs to combat the HIV virus. In 1996, Abbott introduced Norvir as a stand-alone PI with a daily recommended dose of 1,200 milligrams (twelve 100-mg capsules a day), priced at approximately eighteen dollars per day. Norvir is the brand name for a patented compound called ritonavir.

After Norvir’s release, it was discovered that, when used in small quantities with another PI, Norvir would “boost” the antiviral properties of that PI. Not only did a small dose of Norvir — about 100 to 400 milligrams per day — make other Pis more effective and decrease the side effects associated with high doses, but it also slowed the rate at which HIV developed resistance to the effects of those Pis. The use of Norvir as a “booster” has enabled HIV patients to live longer. But the use of Norvir as a booster, and not a stand-alone PI, has also meant that the average daily price of Norvir has plummeted since Nor-vir was first introduced, because patients need a much smaller daily dose of Norvir when it is used as a booster compared to when it is used as a stand-alone PI. By 2003, the average price for a daily dose of Norvir was $1.71.

In 2000, Abbott introduced Kaletra, a single pill containing the PI lopinavir as well as ritonavir, which is used to boost the effects of lopinavir. Although effective and widely used, Kaletra causes some patients to experience significant side effects.

In 2003, two new Pis, Bristol-Myers Squibb’s Reyataz and GSK’s Lexiva, were about to be introduced to the market. Studies showed that, when boosted with Norvir, the new Pis were as effective as Kaletra, and were more convenient. In July, 2003, Reyataz was successfully introduced to the market. As a result, Kale-tra’s market share fell more than Abbott had anticipated. The average daily dose of Norvir also fell. Before Reyataz’s release, the most common boosting dose of Norvir ranged from 200 milligrams to 400 milligrams a day. Clinical trials, however, showed that a Norvir dose of only 100 milligrams a day effectively boosted Reya-taz.

On December 3, 2003, Abbott raised the wholesale price of Norvir by 400 percent while keeping the price of Kaletra constant. Abbott contends that it did this so that the price of Norvir would be more in line with the drug’s enormous clinical value. Plaintiffs contend that the Norvir price increase was an illegal attempt to achieve an anti-competitive purpose in the “boosted market,” which Plaintiffs define as the market for those Pis, such as Reya-taz, Lexiva and Kaletra, that are prescribed for use with Norvir as a booster. Plaintiffs sued for, among other things, monopolization and attempted monopolization in violation of the Sherman Act, 15 U.S.C. § 2 .

LEGAL STANDARD

I. Motion to Dismiss

A complaint must contain a “short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R.Civ.P. 8(a). On a motion under Rule 12(b)(6) for failure to state a claim, dismissal is appropriate only when the complaint does not give the defendant fair notice of a legally cognizable claim and the grounds on which it rests. See Bell Atl. Corp. v. Twombly, — U.S.-, 127 S.Ct. 1955, 1964 , 167 L.Ed.2d 929 (2007). In considering whether the complaint is sufficient to state a claim, the court will take all material allegations as true and construe them in the light most favorable to the plaintiff. NL Indus., Inc. v. Kaplan, 792 F.2d 896, 898 (9th Cir.1986).

II. Motion to Transfer

Title 28 U.S.C. § 1404 (a) provides, “For the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.” The statute itself identifies three factors to consider on a motion to transfer: 1) the convenience of the parties; 2) the convenience of the witnesses; and 3) the interests of justice. 28 U.S.C. § 1404 (a). The Ninth Circuit has articulated other considerations that are subsumed in these basic factors, including: the plaintiffs choice of forum; ease of access to the evidence; the familiarity of each forum with the applicable law; the nexus between the forum and the causes of action; the feasibility of consolidating other claims; any local interest in the controversy; the relative court congestion and time to trial in each forum; the location where the relevant agreements were negotiated and executed; the parties’ contacts with the forums; any difference in the costs of litigation between the two forums; and the availability of compulsory process to compel attendance of unwilling non-party witnesses. Decker Coal Co. v. Commonwealth Edison Co., 805 F.2d 834, 843 (9th Cir.1986); Jones v. GNC Franchising, Inc., 211 F.3d 495, 498-99 (9th Cir.2000). No single factor is dispositive, and a district court has broad discretion to adjudicate motions for transfer on a case-by-case basis. Stewart Org. Inc. v. Ricoh Corp., 487 U.S. 22, 29 , 108 S.Ct. 2239 , 101 L.Ed.2d 22 (1988); Sparling v. Hoffman Constr. Co., Inc., 864 F.2d 635, 639 (9th Cir.1988).

DISCUSSION

I. Cascade’s Application to These Cases

A monopolization claim under § 2 of the Sherman Act requires a plaintiff to prove “(1) possession of monopoly power in the relevant market, (2) willful acquisition or maintenance of that power, and (3) causal ‘antitrust injury.’ ” Rutman Wine Co. v. E. & J. Gallo Winery, 829 F.2d 729, 736 (9th Cir.1987). To demonstrate a claim of attempted monopolization under § 2, the plaintiff must show “(1) that the defendant has engaged in predatory or anticompetitive conduct with (2) a specific intent to monopolize and (3) a dangerous probability of achieving monopoly power.” Cascade, 515 F.3d at 893 . As the Ninth Circuit has noted, the requirements of both claims are similar, “differing primarily in the requisite intent and the necessary level of monopoly power.” Image Technical Servs., Inc. v. Eastman Kodak Co., 125 F.3d 1195 , 1202 (9th Cir.1997).

In the related case, In re Abbott Labs. Norvir Antitrust Litigation, No. C 04-1511, the Court permitted the plaintiffs to proceed on a theory of monopoly leveraging, as articulated in Kodak. Under this theory, “a monopolist who acquires a dominant position in one market through patents and copyrights may violate § 2 if the monopolist exploits that dominant position to enhance a monopoly in another market.” Id. at 1216. Here, Plaintiffs allege that Abbott has exploited its monopoly over the “booster market,” which is comprised only of Norvir, to seek a monopoly over the “boosted market,” which is comprised of drugs intended for use with Norvir as a booster.

As noted above, Abbott has filed an omnibus motion to dismiss based on the Ninth Circuit’s recent decision in Cascade. Cascade addresses the issue of when bundled discounts can be considered anticom-petitive conduct in violation of the Sherman Act. As the court explained:

Cascade, 515 F.3d at 894-95 .

“Bundled discounts generally benefit buyers because the discounts allow the buyer to get more, for less.” Id. at 895 . However, under some circumstances, bundled discounts can be anticompetitive and run afoul of the antitrust laws. This may happen where a firm “enjoys a monopoly on one or more of a group of complementary products, but [] faces competition on others.” Ortho Diagnostic Sys., Inc. v. Abbott Labs., Inc., 920 F.Supp. 455, 467 (S.D.N.Y.1996). The competitor who sells only one product in the bundle, even while producing that product at a lower cost than the monopolist, still “might not be able to match profitably the price created by the multi-product bundled discount. This is true even if the post-discount prices for both the entire bundle and each product in the bundle are above the seller’s cost.” Cascade, 515 F.3d at 896 (citation omitted).

The Ortho court gave an example, which the Cascade decision quotes in its entirety, of how this might happen:

Id. at 896-97 (quoting Ortho, 920 F.Supp. at 467 ).

Thus, “a bundled discounter can exclude rivals who do not sell as great a number of product lines without pricing its products below its cost to produce them,” thereby “aehiev[ing] exclusion without sacrificing any short-run profits.” Id. at 897. For this reason, the test set forth by the Supreme Court to identify illegal predatory pricing in the sale of a single product is not directly applicable to bundled discount cases; that test requires the plaintiff to show that the defendant’s low prices are below its incremental costs — in other words, that the defendant is selling the product at a loss in order to drive out competition. See Brooke Group Ltd. v. Brown & Williamson Tobacco Corp., 509 U.S. 209, 222 , 113 S.Ct. 2578 , 125 L.Ed.2d 168 (1993).

Faced with this difficulty, the Cascade court developed a test to determine when bundled pricing is anticompetitive. After considering various alternatives, the court settled on a “discount attribution” standard:

Cascade, 515 F.3d at 906 . The court believed this standard was in line with the Supreme Court’s direction in Brooke and other cases that low prices, which generally benefit the consumer, should not be condemned unless they are below some measure of the defendant’s cost.

The Cascade court explained how its rule would apply to the shampoo example: The entire discount on the package of products, $2.75, is subtracted from the $3 price of the competitive product, shampoo, when bought separately. The resulting effective price of the shampoo is thus $0.25, well below A’s incremental cost of producing it, $1.50. Accordingly, “A’s pricing practices exclude potential competitors that could produce shampoo more efficiently than A (i.e., at an incremental cost of less than $1.50)” but who are unable to produce shampoo at an incremental cost of $0.25. Id. at 906 n. 15. A’s bundled discount therefore could be considered exclusionary.

After deciding on the discount attribution rule, the court then turned to the appropriate measure of “incremental costs” in a bundled discount case. It noted that there are several possible methods of measuring costs:

Id. at 909 .

The court expressed its approval of the view of Professors Areeda and Turner, set out in their classic law review article, that marginal cost — defined as “the cost to produce one additional unit and the price that would obtain in the market under conditions of perfect competition” — is the “optimal measure of a firm’s costs in a predatory pricing case.” Id.; see also Phillip Areeda & Donald F. Turner, Predatory Pricing and Related Practices Under Section 2 of the Sherman Act, 88 Harv. L.Rev. 697, 712, 716 (1975). Practically speaking, however, it is often not possible to determine the marginal cost from a firm’s accounting practices. Accordingly, the average variable cost, which is more easily determined, must serve as a surrogate for the marginal cost. The Cascade court held, therefore, that average variable cost is the appropriate measure of incremental costs for the bundled pricing standard. Id.

The central question raised by Abbott’s omnibus motion is whether Cascade ’s rule applies in the context of these cases, such that Plaintiffs must show that the imputed price of lopinavir (the competitive product) in Kaletra is below Abbott’s average variable cost of producing it.

As an initial matter, it is far from clear that Abbott’s sale of Kaletra represents a bundled discount. Consumers do not purchase Kaletra because it provides them with a way to save on two products they would otherwise have to purchase separately. In fact, it is not readily apparent that Kaletra consists of two products at all — ritonavir and lopinavir are combined in a single pill. Abbott does not offer lopinavir for sale independently of ritona-vir; lopinavir is not licensed by the FDA for use except as part of Kaletra. Thus, it is not possible for Abbott to offer an actual discount on lopinavir when sold as part of Kaletra.

Abbott’s marketing of Kaletra reveals that Abbott itself does not treat the drug as a package of multiple products — it is offered in an “all or nothing” form. In fact, Abbott’s expert in In re Abbott Labs. Norvir Antitrust Litigation explicitly argues in his rebuttal report that a bundled discount theory does not apply to Abbott’s pricing structure — the relevant heading is entitled, “Abbott does not offer bundled discounts, nor is the challenged pricing structure economically equivalent to bundled discounts.” Pis.’ Req. For Judicial Notice Ex. 1 at 18. Abbott’s expert states:

Id.

Even if Kaletra represents a bundled discount such that these cases fall within the general purview of Cascade, it does not follow that the Court must mechanically apply the Cascade rule regardless of its effect under the circumstances. Cascade itself implicitly acknowledges that some atypical cases may fall outside of the situation where only below-cost pricing will have the effect of inhibiting competition. In discussing the application of Brooke to bundled pricing cases, the Cascade court noted that the Supreme Court has never gone “so far as to hold that in every case in which a plaintiff challenges low prices as exclusionary conduct the plaintiff must prove that those prices were below cost.” Cascade, 515 F.3d at 901 . Instead, the Ninth Circuit viewed the Supreme Court’s opinions as “strongly suggesting] that, in the normal case, above-cost pricing will not be considered exclusionary conduct for antitrust purposes.” Id. (emphasis added).

Abbott’s sale of Kaletra — if it represents a bundled discount — is a strong candidate for the exception contemplated by the Ninth Circuit. This is because the stated goal of the Cascade rule — making unlawful only pricing that would exclude equally efficient competitors from the market— would not be served by applying the rule here.

To illustrate why this is the case, it is instructive to apply the rule to the facts. Abbott charges $17.14 for 200 milligrams of Norvir, while charging $18.78 for a dose of Kaletra containing the same amount of ritonavir. Norris Dec. (Docket No. 20, Case No. 07-5985) Ex. A at 8. The imputed price of the lopinavir portion of Kaletra is the difference between the two amounts, or $1.64. Therefore, under a straightforward application of the Cascade rule, Abbott’s pricing could be found anticompeti-tive only if its average variable cost of producing lopinavir is greater than $1.64.

As the parties note, the cost of manufacturing Kaletra pills is negligible — most likely only a few cents per pill. Assuming for the sake of argument that Abbott’s average variable cost of producing lopina-vir is $0.05, if the Cascade rule applied, Abbott’s sale of the drug for $1.64 cannot be an antitrust violation. In fact, at a hypothetical production cost of $0.05, the Cascade rule would permit Abbott to sell Nor-vir at a price of up to $18.73.

But at such a price, competitors would have to sell an equally effective product for $0.05 or less in order to compete with Kaletra. Common sense dictates that no newly developed PI could ever be sold profitably at such a price, because the manufacturer would never be able to recoup its huge research and development costs. If the Cascade rule were applied in this context, it would stifle competition; even a competitor who could produce an equally effective drug for only $0.01 per pill would be excluded from the market. Thus, as applied here, the Cascade rule does not achieve its stated goal of prohibiting pricing that results in the exclusion of equally efficient competitors. This failure is attributable to the unique structural characteristics of the pharmaceutical industry, where fixed costs in the form of investment in research and development dwarf variable costs.

More fundamentally, using average variable cost as a gauge of anticompetitive pricing leads to an exclusive concern with promoting manufacturing efficiency. But such a concern is not relevant here, where the goal is to prevent pricing that would exclude new, equally effective Pis from competing with lopinavir, provided those Pis can be developed and introduced at least as efficiently as lopinavir. The present cases are not concerned with the potential exclusion of equally efficient manufacturers of lopinavir. Yet the Cascade rule is equipped only to address this latter scenario.

An antitrust doctrine that seeks exclusively to promote the efficient production of pills will not serve to promote the introduction of new medicines to compete with a patented drug. An appropriate antitrust rule here should have the effect of prohibiting Abbott’s pricing practices if a hypothetical equally efficient developer of an equally effective PI would not be able to profit if it introduced that PI to the market at a price of $1.64, the imputed price of lopinavir. As demonstrated, the average-variable-cost rule does not accomplish that goal. Accordingly, the Court concludes that the present cases fall within the exception contemplated by Cascade, and thus Plaintiffs need not allege or show that the imputed price of the lopinavir portion of Kaletra is less than Abbott’s average variable cost of producing it.

II. Monopolization of the Boosting Market

The Meijer, Rochester and Louisiana Plaintiffs assert a Sherman Act claim that the other Plaintiffs do not: they allege that Abbott illegally monopolized the' boosting market by keeping the price of Norvir low, thereby providing little incentive for competitors to develop products to compete with it or technologies to reduce the amount of Norvir that must be used as a boosting agent, then raising prices. The other Plaintiffs assert only that Abbott monopolized the boosted market.

Abbott claims that its patents entitle it to a monopoly in the boosting market. However, the extent of Abbott’s exclusionary rights under its patents is not clear from the face of the complaint. Thus, dismissal of this claim is premature, and Abbott’s motion is denied.

III. Abbott’s Motion to Dismiss GSK’s Claims

A. Sherman Act Claims

In its order denying Abbott’s motion for summary judgment in In re Abbott Labs. Norvir Antitrust Litigation, the Court found that there was a triable issue of fact regarding whether Abbott’s patent rights extend beyond the booster market to the boosted market, thereby entitling it to maintain a monopoly over the latter market. Abbott maintains that, in the SmithKline Beecham complaint, GSK admits that Abbott’s patents cover the boosted market, essentially “pleading itself out of court.”

In support of its argument, Abbott cites the following paragraphs of the complaint:

Compl., Case No. C 07-5702.

Contrary to Abbott’s characterization of these statements, they do not admit or necessarily imply that Abbott has a valid patent covering the entire boosted market.

Nor is GSK precluded from asserting its claims by virtue of its license agreement with Abbott, which gives GSK the right to market its own Pis for use with Norvir as a booster. As this Court has noted previously, a party may choose to obtain a license, even under the belief that the licensed patent is invalid or does not cover the scope claimed by the patentee, in order to avoid the possibility of litigation. Cf. MedImmune v. Genentech, Inc., 549 U.S. 118 , 127 S.Ct. 764 , 166 L.Ed.2d 604 (allowing a current licensee to bring an action for a declaratory judgment of noninfringement and invalidity).

Abbott also notes that the license contains a recital stating, “Abbott owns certain patents related to the use, marketing and promotion of Ritonavir (as defined below), its protease inhibiting compound (marketed under the trade name Norvir), in combination with other products indicated for the treatment of HIV.” Norris Dec. Ex. A at 1. This recital, however, does not specify that Abbott possesses valid patents giving it the rights it now claims over the boosted market. Even if it did, such a statement would not constitute a binding admission in this litigation, in that it is not a promise comprising a part of the bargained-for exchange that is the subject of the license agreement.

B. State Law Claims

1. Breach of the Implied Covenant of Good Faith and Fair Dealing

GSK asserts a claim for breach of the implied covenant of good faith and fair dealing under New York law, which applies pursuant to the choice-of-law provision in the license agreement. In connection with this claim, GSK asserts that it was deprived of the benefit of the license agreement’s bargain when Abbott raised the price of Norvir. GSK maintains that, when it agreed to pay substantial royalties for the right to market its Pis for use in conjunction with Norvir, it had a “reason able expectation that Norvir would continue to be commercially available for use as a PI boosting agent and that future increases in the price of Norvir would be consistent with past increases.” Smith-Kline Beecham Compl. ¶ 64. When Abbott raised the price of Norvir, GSK claims it acted in bad faith by intentionally “thwart[ing] GSK’s ability to benefit from [its] contracted rights.” Id.

Under New York law, “[i]mplicit in all contracts is a covenant of good faith and fair dealing in the course of contract performance.” Dalton v. Educ. Testing Serv., 87 N.Y.2d 384 , 639 N.Y.S.2d 977 , 663 N.E.2d 289, 291 (1995). Abbott has cited lower court cases from New York holding that a claim for breach of the implied covenant of good faith and fair dealing cannot take the place of a substantively nonviable breach of contract claim, see e.g., Nikitovich v. O’Neal, 40 A.D.3d 300 , 836 N.Y.S.2d 34 (App.Div.2007), and that a claim for the breach of the implied covenant of good faith and fair dealing may not be asserted independently of a breach of contract claim when it is based on the same facts, see, e.g., Cohen v. Nassau Educators Fed. Credit Union, 2006 WL 1540324 , at *4 (N.Y.Sup.Ct.2006). Neither of these is the situation here.

In addition, the New York Court of Appeals has held that a breach of the implied covenant of good faith and fair dealing can itself serve as the basis for a breach of contract claim. In 511 West 232nd Owners Corp. v. Jennifer Realty Co., 98 N.Y.2d 144 , 746 N.Y.S.2d 131 , 773 N.E.2d 496 (2002), the court permitted the plaintiffs to proceed on a breach of contract claim based on their allegation that the offering plan for the conversion of an apartment building into a cooperative included an implied promise by the sponsor to sell all unsold units within a reasonable time. Such a promise was not explicitly contained in the contract. The court held that, “[w]hile the duties of good faith and fair dealing do not imply obligations inconsistent with other terms of the contractual relationship,” they do require that “neither party shall do anything which will have the effect of destroying or injuring the right of the other party to receive the fruits of the contract.” Id. at 135, 773 N.E.2d at 500 (internal quotation marks omitted). Accordingly, a party may pursue a breach of contract claim for violation of “any promises which a reasonable person in the position of the promisee would be justified in understanding were included.” Id. at 136, 773 N.E.2d at 501 (internal quotation marks omitted).

Here, GSK’s second cause of action is entitled, “Breach of Covenant of Good Faith and Fair Dealing,” not breach of contract. To the extent Abbott argues that this claim should be dismissed because it must be stated as a breach of contract claim, its argument fails. “The form of the complaint and the label attached by the pleader are not controlling, and it is enough that the pleader state the facts making out a cause of action.” Drezin v. DeLisser, 17 Misc.3d 706 , 847 N.Y.S.2d 409 , 413-14 (Sup.Ct.2007) (citing Van Gaasbeck v. Webatuck Cent. School Dist. No. 1, 21 N.Y.2d 239 , 287 N.Y.S.2d 77 , 234 N.E.2d 243 (1967)). GSK alleges that Abbott undertook an implied obligation to continue to make Norvir commercially available and to keep future increases in the price of Norvir in line with past increases. Whether Abbott in fáct undertook such an obligation is an issue of fact that is not appropriately determined on a motion to dismiss. Because such an implied obligation would not necessarily be inconsistent with the express terms of the license agreement, the Court finds that GSK has sufficiently plead a claim for breach of an implied term of the license agreement.

2. North Carolina Unfair Trade Practices Act and Prohibition Against Monopolization

Abbott argues that GSK has failed to state a claim under the North Carolina Unfair Trade Practices Act, N.C. Gen.Stat. § 75-1.1. To state such a claim, a plaintiff must allege: “(1) an unfair or deceptive act or practice, or unfair method of competition, (2) in or affecting commerce, and (3) which proximately caused actual injury to the plaintiff or his business.” Miller v. Nationwide Mut. Ins. Co., 112 N.C.App. 295 , 435 S.E.2d 537, 542 (1993). The Act is a “comprehensive law designed to include within its reach the federal antitrust laws.” L.C. Williams Oil Co., Inc. v. Exxon Corp., 625 F.Supp. 477, 481 (M.D.N.C.1985). Accordingly, Sherman Act violations are likely to be actionable under the Unfair Trade Practices Act. Additionally, the North Carolina Act “also sanctions, as part of its broad remedial purpose of promoting ethical business dealings, commercial ‘unfairness’ and ‘deception’ beyond traditional antitrust concepts.” Id. (citing Marshall v. Miller, 302 N.C. 539 , 276 S.E.2d 397, 403 (1981)).

North Carolina courts apparently have not addressed whether a cause of action based on a monopoly leveraging theory may lie under the Unfair Trade Practices Act. Accordingly, the Court must predict how the North Carolina Supreme Court would resolve this issue. See Westlands Water Dist. v. Amoco Chem. Co., 953 F.2d 1109 , 1111 (9th Cir.1991).

Abbott argues that the North Carolina Supreme Court would follow the Seventh Circuit and the Federal Circuit in rejecting liability under a monopoly leveraging theory. However, Abbott has cited no North Carolina case or any other evidence in support of this contention, and thus has provided no basis for the Court to apply a different antitrust standard than that which it has applied to GSK’s Sherman Act claim. In addition, even if the North Carolina Supreme Court would not recognize monopoly leveraging as a form of anticompetitive conduct, GSK has alleged conduct that could be considered “unfair” or “deceptive” under the Act. Accordingly, GSK may proceed on its claim.

IV. Abbott’s Motion to Transfer the SmithKline Beecham Case

Abbott seeks to transfer the SmithKline Beecham case to Illinois. It is true that the only apparent connection between the case and California is that California is home to a large number of HIV-positive individuals who may be consumers of boosted Pis. However, this case has no greater connection to Illinois, except that Illinois is the site of Abbott’s headquarters. Illinois thus has no particular interest in this case other than the generalized interest in ensuring that its citizens receive fair adjudications.

While Abbott claims that transferring the case to Illinois would be more convenient for it, this claim is undercut by the fact that Abbott would continue to have to defend itself in the related cases still before this Court, while defending itself in a new forum as well. Moreover, GSK apparently finds California to be a convenient forum, and it would not be appropriate to transfer this case on convenience grounds when the effect would be simply to make the litigation more convenient for one party at the expense of the other party. See STX, Inc. v. Trik Stik, Inc., 708 F.Supp. 1551, 1556 (N.D.Cal.1988); Decker Coal, 805 F.2d at 848 .

Additionally, it would not be in the interest of justice to transfer this case because it would needlessly splinter the litigation. Nor has Abbott shown that the availability of witnesses or evidence will be an issue if the case continues in this District, particularly considering that the related cases will continue before the Court whether Smith-Kline Beecham is transferred or not. As for Abbott’s charge that GSK has engaged in forum shopping, it appears equally likely that Abbott is engaging in similar conduct; by litigating the case in Illinois, Abbott would be able to rely on Seventh Circuit precedent, which is more favorable to Abbott than Ninth Circuit precedent.

Accordingly, the Court declines to exercise its discretion to transfer this case to Illinois.

CONCLUSION

For the foregoing reasons, Abbott’s motions to dismiss are DENIED. Abbott’s motion to transfer the SmithKline Beec-ham case is also DENIED.

IT IS SO ORDERED.

. Abbott argues that Federal Circuit law bars Plaintiffs’ reliance on a monopoly leveraging theory, citing In re Independent Service Organizations Antitrust Litigation, 203 F.3d 1322 (Fed.Cir.2000), in support of its position. According to Abbott, the scope of its rights depends on the resolution of a substantial question of federal patent law, and therefore the Federal Circuit has jurisdiction over any appeal. The Court considered and rejected this argument in In re Abbott Labs. Norvir Antitrust Litigation, and it adheres to that decision. Kodak clearly touched upon the limits of a patentee's rights, and yet the Ninth Circuit crafted a rule as a matter of federal antitrust law, based on Supreme Court precedent. To the extent Federal Circuit law interprets that same precedent in a way that would warrant dismissal of Plaintiffs’ claims (and it is not clear that Independent Service Organizations would in fact require dismissal), the Court will follow the Ninth Circuit because those claims arise under the Sherman Act, not federal patent law. . Exclusionary bundled pricing is not necessarily mutually exclusive with a monopoly leveraging theory; bundled pricing can serve as the means by which a plaintiff exploits its monopoly in one market to enhance its monopoly in another market. Thus, both Kodak and Cascade hypothetically could apply at the same time. . The Court grants Plaintiffs’ request for judicial notice of this portion of the expert rebuttal report. . These figures are found in a Health and Human Services letter referred to in the complaint. The Court uses them for illustrative purposes, not as evidence in support of its decision. . Because Abbott does not sell lopinavir separately, the price of unbundled lopinavir cannot be used as a starting point for the calculation, as the Cascade rule contemplates will ordinarily be done. Nonetheless, only two variables are required in order to derive the "discounted price” of lopinavir. To demonstrate this, assume that Abbott sells lopinavir separately for price "x.” The cumulative discount represented by Kaletra would then be x + $17.14 — $18.78, or x — $1.64, all of which must be allocated to the lopinavir por-lion pursuant to the rule. Subtracting the discount of x — $1.64 from the price of lopina-vir, x, results in an imputed discounted price of $1.64. .The Meijer Plaintiffs argue that Abbott’s average variable costs should include more than just the cost of manufacturing; they argue that marketing and promotion costs should also be included. This is a valid argument, and would raise the average variable cost above the pennies-per-pill cost of manufacturing. However, because the Court finds that the Cascade rule does not apply, it need not determine whether marketing and similar costs should be considered when calculating Abbott’s average variable cost. .It is notable that Cascade and the law review article on which it relies are based on the premise that, in a perfectly competitive market, the market price will equal the marginal cost. See Cascade, 515 F.3d at 909 ; Areeda & Turner, supra, at 702. However, in the pharmaceutical industry, even in a crowded field of competing drugs, market prices will typically be well above marginal costs. See, e.g., Peter K. Yu, the International Enclosure Movement, 82 Ind. L.J. 827 , 898 n. 377 (2007) (“The model of price-setting in a perfectly competitive market suggests that prices are based upon marginal costs. But this model obviously does not apply for pharmaceuticals, for if they were priced according to their marginal costs, they would be very inexpensive, but in the long run no expenditures on R & D would be made.”); Brianna Carignan, Legalizing Importation of Prescription Drugs: The Economic Implications of the Pharmaceutical Marlcet Access and Drug Safety Act of 2005, 12 New Eng. J. Int'l & Comp. L. 161, 165 (2005) ("[T]he developer of a drug could never recover its research and development costs by charging prices near its marginal cost of production. The economic purpose of patents is to bar entry of copy products for the term of the patent, to provide the innovator firm with an opportunity to price above marginal cost and thereby recoup R & D expense, in order to preserve incentives for future R & D. Without patents, generic pharmaceuticals could enter the market immediately and price at marginal cost because they would not have any R & D expenses to recover.”) (citation, internal quotation marks and alterations omitted). Abbott notes that Cascade involves bundled discounting in the provision of healthcare services. Abbott asserts that the healthcare services industry is one with high fixed costs, and thus pharmaceutical cases cannot be distinguished from Cascade. However, while the provision of healthcare services may involve high fixed costs, variable costs — including the cost of compensating medical professionals for their time — are high as well. As a result, the healthcare services industry does not exhibit the great disparity between fixed and variable costs found in the pharmaceutical industry. . In contrast, manufacturing efficiency is an appropriate focus when the issue is competition between different manufacturers of a single drug for which the patent has expired. Accordingly, the Cascade rule would achieve the desired effect when applied in such a case. . It may be possible to adjust the rule to shift the focus away from the marginal cost of manufacturing pills. For instance, it may be appropriate to require Plaintiffs to show, not that $1.64 is less than Abbott’s cost of producing 200 milligrams of lopinavir, but that $1.64 is not a profitable price for the sale of a 200-mg dose of lopinavir, taking into account the costs Abbott incurred prior to introducing lo-pinavir to the market. Such a "modified” Cascade rule may be difficult to implement in practice. For instance, if Abbott has already recouped its investment in lopinavir, $1.64 may be a profitable price for it today, even if Abbott could not have hoped to recoup its investment by selling lopinavir for $1.64 when it was first introduced to the market. At the same time, asking if $1.64 would have been a profitable price for lopinavir when Abbott first introduced it to the market would require the development of complex economic models that depend on variables which may not be readily ascertainable. . In their briefs on the present motions, these Plaintiffs articulate two theories of antitrust liability that the plaintiffs in In re Abbott Labs Norvir Antitrust Litigation have not asserted. Because the complaints in the present cases do not assert separate claims based on these "new” theories, however, the Court need not rule on their validity. The Court thus addresses only whether Plaintiffs may proceed on their claims for monopolization and attempted monopolization under the Sherman Act. . In addition, Abbott’s argument presupposes that it will raise its patents as an affirmative defense. Because this defense does not appear clearly on the face of the pleading, dismissal at this stage is not appropriate in any event. . The only case Abbott cites is a federal case in which the court predicted that the Fourth Circuit would not find a violation of § 2 of the Sherman Act based on a monopoly leveraging theory. Bepco, Inc. v. Allied-Signal, Inc., 106 F.Supp.2d 814, 833 (M.D.N.C.2000). This sheds no light on the question of whether the North Carolina Supreme Court would accept such a theory under the Unfair Trade Practices Act. Moreover, the Bepco court permitted the plaintiffs to proceed on their claims under the Unfair Trade Practices Act. . For the same reason, GSK has also stated a claim under the North Carolina Prohibition Against Monopolization, N.C. Gen.Stat. § 75-2.1. .Abbott argues that, in order for a claim for deceptive behavior to lie, there must be detrimental reliance upon a statement or misrepresentation, citing Business Cabling, Inc. v. Yokeley, 182 N.C.App. 657 , 643 S.E.2d 63, 69 (N.C.Ct.App.2007), in support of its position. Yokeley , however, was concerned with determining whether the plaintiff had established causation between the deceptive acts and a compensable injury. No such issue is present here. In addition, another North Carolina appeals court has held that actual reliance on a misrepresentation is not required. See Cullen v. Valley Forge Life Ins. Co., 161 N.C.App. 570 , 589 S.E.2d 423, 431 (N.C.Ct.App.2003).